ERBB2 and breast neoplasm: In a pilot study, eight primary breast tumor tissues were scrutinized by scWB, including four HER2-IHC 3+ patients, one HER2-IHC 2+ patient, and two HER2-IHC negative (0 or 1+) patients with T1–T4 tumor stage, with either positive or negative lymph node status.